Professor of Biochemistry, Biozentrum of the University of Basel, Switzerland
The 2017 Selection Committee announced cell growth research pioneer Michael N. Hall will receive the 2017 Szent-Györgyi Prize for Progress in Cancer Research.
In 1991, Hall discovered one of the most important cancer cell targets in the modern era of oncology, which he named “Target of Rapamycin” or TOR. He discovered that TOR – a conserved protein kinase – controls cell growth and a wide range of metabolic processes that when dysregulated cause disorders such as cancers, cardiovascular disease, diabetes and obesity. TOR inhibitors are used today in treatments for kidney, breast, brain and pancreatic cancers, and numerous clinical trials are currently underway testing TOR inhibitors in the treatments of many types of cancer.
This first-of-its-kind occasion will feature a trio of programs celebrating cancer research success and the impact of oncology innovation. The event will be held live at the National Press Club in Washington, DC, and streamed online with virtual interactions and networking.Celebrating Cancer Research Progress and Entrepreneurship
Cancer Research is one of the most important things there is. It impacts such a huge number of people and I like that I can help the cause.Jerry Harrington, Donor, Fly to Find a Cure
Donating to the National Foundation for Cancer Research’s Fly to Find a Cure program makes me feel like I’m helping people everywhere, including myself. It’s always wonderful to get the extra mileage to visit the places I want to go.Betty Locke, Donor, Fly to Find a Cure
As one of the first to support GBM AGILE, we recognized the immediate impact it would have on cancer treatment and care for patients around the world.”Sujuan Ba, PhD, NFCR President & CEO